TMS Co., Ltd. (JP:4891) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TMS Co., Ltd. has announced the publication of Phase 2a clinical trial results for JX10 (TMS-007), a potential treatment for acute ischemic stroke, in a leading medical journal. The study demonstrated significant efficacy and safety, highlighting JX10’s potential as a novel therapeutic option with an extended treatment window. This development marks a promising step forward in addressing the needs of a largely underserved patient population.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.